GLYCAN-CONJUGATED ANTIBODIES BINDING TO FC-GAMMA RECEPTOR
The present invention provides antibody-conjugates which are conjugated via the glycan and still bind to a cell comprising an Fc-gamma receptor. The antibody conjugates according to the invention have structure (1):Ab-[(GlcNAc(Fuc)b-(G)e-(Su-(Z-L-(D)r)x)s]y (1)Herein, Ab is an antibody; GlcNAc is an N-acetylglucosamine moiety; Fuc is a fucose moiety; b is 0 or 1; G is a monosaccharide; e is an integer in the range of 4-10; Su is a monosaccharide; Z is a connecting group obtained by a cycloaddition or a nucleophilic reaction; L is a linker; D is a payload; s is 1 or 2; r is an integer in the range of 1-4; x is 1 or 2; y is 2 or 4..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 01. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
VAN DELFT FLORIS LOUIS [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-01, Last update posted on www.tib.eu: 2023-11-21, Last updated: 2023-11-24 |
|---|
| Patentnummer: |
EP4267195 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018438970 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018438970 | ||
| 003 | DE-627 | ||
| 005 | 20231124094927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231110s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018438970 | ||
| 035 | |a (EPA)EP4267195 | ||
| 035 | |a (EPA)73943179 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a VAN DELFT FLORIS LOUIS |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a GLYCAN-CONJUGATED ANTIBODIES BINDING TO FC-GAMMA RECEPTOR |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-01, Last update posted on www.tib.eu: 2023-11-21, Last updated: 2023-11-24 | ||
| 520 | |a The present invention provides antibody-conjugates which are conjugated via the glycan and still bind to a cell comprising an Fc-gamma receptor. The antibody conjugates according to the invention have structure (1):Ab-[(GlcNAc(Fuc)b-(G)e-(Su-(Z-L-(D)r)x)s]y (1)Herein, Ab is an antibody; GlcNAc is an N-acetylglucosamine moiety; Fuc is a fucose moiety; b is 0 or 1; G is a monosaccharide; e is an integer in the range of 4-10; Su is a monosaccharide; Z is a connecting group obtained by a cycloaddition or a nucleophilic reaction; L is a linker; D is a payload; s is 1 or 2; r is an integer in the range of 1-4; x is 1 or 2; y is 2 or 4. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a VAN BERKEL SANDER SEBASTIAAN |4 aut | |
| 700 | 0 | |a VAN GEEL REMON |4 aut | |
| 700 | 0 | |a LELIEVELDT LIANNE |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 01. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/73943179/publication/EP4267195A1?q=EP4267195 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 01 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 11 | ||